Ocular and Systemic Determination of and Tumour Necrosis Factor in a Patient with Ocular Inflammation
暂无分享,去创建一个
[1] R. Thompson,et al. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. , 1991, Immunology today.
[2] C. Dinarello. Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.
[3] H. Tessler,et al. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. , 1990, The British journal of ophthalmology.
[4] V. Trinkaus-Randall,et al. Development of a biopolymeric keratoprosthetic material. Evaluation in vitro and in vivo. , 1988, Investigative ophthalmology & visual science.
[5] M. Cybulsky,et al. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. , 1987, The American journal of pathology.
[6] H. Shepard,et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.
[7] R. Nussenblatt,et al. Anti-retinal auto-antibodies in Vogt-Koyanagi-Harada syndrome, Behcet's disease, and sympathetic ophthalmia. , 1985, Ophthalmology.
[8] S. Azen,et al. Histocompatibility antigens in sympathetic ophthalmia. , 1983, American journal of ophthalmology.
[9] N. Rao,et al. The role of the penetrating wound in the development of sympathetic ophthalmia experimental observations. , 1983, Archives of ophthalmology.
[10] G. E. Marak. Recent advances in sympathetic ophthalmia. , 1979, Survey of ophthalmology.